Jacob M. Rowe

16.2k total citations · 3 hit papers
237 papers, 11.1k citations indexed

About

Jacob M. Rowe is a scholar working on Hematology, Materials Chemistry and Molecular Biology. According to data from OpenAlex, Jacob M. Rowe has authored 237 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Hematology, 50 papers in Materials Chemistry and 42 papers in Molecular Biology. Recurrent topics in Jacob M. Rowe's work include Acute Myeloid Leukemia Research (83 papers), Nuclear Physics and Applications (31 papers) and Acute Lymphoblastic Leukemia research (31 papers). Jacob M. Rowe is often cited by papers focused on Acute Myeloid Leukemia Research (83 papers), Nuclear Physics and Applications (31 papers) and Acute Lymphoblastic Leukemia research (31 papers). Jacob M. Rowe collaborates with scholars based in United States, Israel and Germany. Jacob M. Rowe's co-authors include Martin S. Tallman, J. J. Rush, Frederick R. Appelbaum, Cheryl L. Willman, Peter H. Wiernik, J. R. D. Copley, James H. Feusner, Peter A. Cassileth, Elisabeth Paietta and David R. Head and has published in prestigious journals such as Science, New England Journal of Medicine and Physical Review Letters.

In The Last Decade

Jacob M. Rowe

232 papers receiving 10.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

2000 1.2k citations Cheryl L. Willman, Jacob M. Rowe et al. Blood profile →
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia

1997 806 citations Martin S. Tallman, Janet W. Andersen et al. New England Journal of Medicine profile →
Crystal Dynamics of Copper

1967 242 citations Jacob M. Rowe et al. profile →

Peers

Countries citing papers authored by Jacob M. Rowe

Since Specialization

Citations

This map shows the geographic impact of Jacob M. Rowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacob M. Rowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacob M. Rowe more than expected).

Fields of papers citing papers by Jacob M. Rowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacob M. Rowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacob M. Rowe. The network helps show where Jacob M. Rowe may publish in the future.

Co-authorship network of co-authors of Jacob M. Rowe

This figure shows the co-authorship network connecting the top 25 collaborators of Jacob M. Rowe. A scholar is included among the top collaborators of Jacob M. Rowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacob M. Rowe. Jacob M. Rowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction 2025 ·Blood Advances ·(unknown), Alexander R. Terry, Andriy Derkach, (unknown), Kuo‐Kai Chin, Yannis K. Valtis, (unknown), (unknown), Wenbin Xiao, Christopher Famulare, (unknown), Jacob M. Rowe, Martin S. Tallman, Eytan M. Stein	0
2	Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials 2024 ·Bone Marrow Transplantation ·Chezi Ganzel, Yihua Wang, (unknown), Zijie Sun, Jacob M. Rowe, Hugo F. Fernández, Elisabeth Paietta, S. M. Luger, Hillard M. Lazarus, Larry D. Cripe, Dan Douer, Peter H. Wiernik, Martin S. Tallman, Mark R. Litzow	1
3	Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling 2022 ·Leukemia Research ·Chezi Ganzel, Zhuoxin Sun, Timour Baslan, Yanming Zhang, Mithat Gönen, Omar Abdel‐Wahab, Janis Racevskis, Francine E. Garrett-Bakelman, Scott W. Lowe, Hugo F. Fernández, Rhett P. Ketterling, Selina M. Luger, Mark R. Litzow, Hillard M. Lazarus, Jacob M. Rowe, Martin S. Tallman, Ross L. Levine, Elisabeth Paietta	5
4	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study 2019 ·Blood ·James M. Foran, Zhuoxin Sun, David F. Claxton, Hillard M. Lazarus, Daniel A. Arber, Jacob M. Rowe, Elisabeth Paietta, Janis Racevskis, Jessica K. Altman, Selina M. Luger, Aref Al‐Kali, Hong Zheng, Keith W. Pratz, E. Randolph Broun, Bayard L. Powell, Kristen M. O’Dwyer, John E. Godwin, Yishai Ofran, Mark R. Litzow, Martin S. Tallman	24
5	FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years 2018 ·Blood ·James M. Foran, Zhuoxin Sun, Elisabeth Paietta, Janis Racevskis, David F. Claxton, Hillard M. Lazarus, Daniel A. Arber, Jacob M. Rowe, John E. Godwin, Yanming Zhang, Martin S. Tallman, Mark R. Litzow, Keith W. Pratz, Selina M. Luger	4
6	Synergistic antileukemic therapies in NOTCH1-induced T-ALL 2017 ·Clinical Cancer Research ·(unknown), Alberto Ambesi‐Impiombato, Yue Qin, Daniel Herranz, Mukesh Bansal, Tiziana Girardi, Elisabeth Paietta, Martin S. Tallman, Jacob M. Rowe, Kim De Keersmaecker, Andrea Califano, Adolfo A. Ferrando	1
7	Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008 2016 ·Journal of Clinical Oncology ·Chezi Ganzel, Judith Manola, Dan Douer, Jacob M. Rowe, Hugo F. Fernández, Elisabeth Paietta, Mark R. Litzow, Ju-Whei Lee, Selina M. Luger, Hillard M. Lazarus, Larry D. Cripe, Peter H. Wiernik, Martin S. Tallman	85
8	Acute Myeloid Leukemia in Adolescents and Young Adults: Challenging Aspects 2014 ·Acta Haematologica ·Jacob M. Rowe, Yishai Ofran, Jacob M. Rowe	28
9	Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid 2011 ·Blood ·Jae H. Park, Baozhen Qiao, Katherine S. Panageas, Maria J. Schymura, Joseph G. Jurcic, Todd Rosenblat, Jessica K. Altman, Dan Douer, Jacob M. Rowe, Martin S. Tallman	279
10	ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. 2005 ·UCL Discovery (University College London) ·Jacob M. Rowe, Georgina Buck, (unknown), (unknown), (unknown), Stephen M. Richards, (unknown), I M Franklin, (unknown), (unknown), (unknown), Jill Durrant, (unknown), (unknown)	5
11	Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. 2005 ·PubMed ·Yona Nadir, Tamar Katz, Galit Sarig, Ron Hoffman, (unknown), Jacob M. Rowe, Benjamin Brenner	34
12	The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years. 2003 ·Blood ·(unknown), (unknown), Georgina Buck, Michael Richards, James Franklin, Hillard M. Lazarus, (unknown), Martin S. Tallman, H. G. Prentice, Jill Durrant, Jacob M. Rowe	9
13	Long-term follow-up and potential for cure in acute promyelocytic leukaemia 2003 ·Best Practice & Research Clinical Haematology ·Martin S. Tallman, Jacob M. Rowe	9
14	The NIST Center for Neutron Research 2001 ·APS ·Jacob M. Rowe	1
15	Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) Plus Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC) 1999 ·Advances in experimental medicine and biology ·Ranjana H. Advani, Giuseppe Visani, D Milligan, (unknown), Martin S. Tallman, Jacob M. Rowe, Peter H. Wiernik, (unknown), Kathleen Dugan, B L Lum, (unknown), Eric Davis, Elisabeth Paietta, Manuel Litchman, A. Covelli, Branimir I. Šikić, Peter L. Greenberg	33
16	Acute leukemia forum '98 : advances and controversies in the biology and treatment of acute myelogenous leukemia and myelodysplasia : symposium proceedings, March 6, 1998, San Francisco, California, USA 1998 ·Jacob M. Rowe	2
17	All-trans-Retinoic Acid in Acute Promyelocytic Leukemia breakdown → 1997 ·New England Journal of Medicine ·Martin S. Tallman, Janet W. Andersen, Charles A. Schiffer, Frederick R. Appelbaum, James H. Feusner, Angela Ogden, Lois E. Shepherd, Cheryl L. Willman, Clara D. Bloomfield, Jacob M. Rowe, Peter H. Wiernik	806
18	Does In Vitro Bone Marrow Purging Improve the Outcome after Autologous Bone Marrow Transplantation? 1993 ·Journal of Hematotherapy ·Hillard M. Lazarus, Jacob M. Rowe, Anthony H. Goldstone	8
19	Treatment of relapsed or refractory Hodgkin disease and non‐Hodgkin lymphoma with high‐dose chemoradiotherapy followed by unstimulated autologous peripheral stem cell rescue 1992 ·American Journal of Hematology ·Aaron P. Rapoport, Jacob M. Rowe, Joanna M. Heal, Martin A. Tanner, John F. DiPersio	3
20	Acoustic microscopy of surface cracks 1986 ·Philosophical Transactions of the Royal Society of London Series A Mathematical and Physical Sciences ·Jacob M. Rowe, Jun‐ichi Kushibiki, Michael G. Somekh, G. A. D. Briggs	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact